Post Marketing Data: Adverse drug reactions (ADRs) identified during post-marketing experience with bromhexine and guaifenesin or the combination of bromhexine and guaifenesin are presented in Table 1 and Table 2. The frequencies are provided according to the following convention: Very common ≥1/10; Common ≥1/100 and <1/10; Uncommon ≥1/1,000 and <1/100; Rare ≥1/10,000 and <1/1,000; Very rare <1/10,000; Not known (cannot be estimated from the available data). (See Tables 1 and 2.)


View ADR Reporting Link